AUTL Autolus Therapeutics plc

NASDAQ
$1.14

Autolus Therapeutics plc (AUTL) is expected to report earnings on February 9, 2027, before the market open. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.8% since its last earnings release on November 10, 2026.

Autolus Therapeutics plc Beat Expectations, Guides to the High End of its Previous Guidance Range
Tuesday, November 10, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.20)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.24

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.